Max Chat
Share chart Kymera Therapeutics, Inc.
Extended chart
Simple chart
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., биофармацевтическая компания, фокусируется на открытии и разработке новых терапевтических средств на малых молекулах, которые избирательно разрушают вызывающие заболевание белки, используя собственную естественную систему расщепления белков организма. Он участвует в разработке программы IRAK4 для лечения иммунологических воспалительных заболеваний, включая гнойный гидраденит, атопический дерматит и ревматоидный артрит; Программа IRAKIMiD для лечения диффузной крупноклеточной В-клеточной лимфомы с мутацией MYD88; и программа STAT3 для лечения гематологических злокачественных новообразований и солидных опухолей, а также аутоиммунных заболеваний. Компания была основана в 2015 году, ее штаб-квартира находится в Уотертауне, штат Массачусетс.
Main settings
IPO date
2020-08-21
ISIN
US5015751044
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 64.14 | 1 |
| P/BV | 3.61 | 5 |
| P/E | 71.85 | 1 |
Efficiency
| Title | Value | Grade |
| ROA | -28.81 | 0 |
| ROE | -36.38 | 0 |
| ROIC | -33.64 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.4059 | 10 |
| Debt/Ratio | 0.0897 | 10 |
| Debt/Equity | 0.1704 | 10 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 38.45 | 5 |
| Yield Ebitda, % | 375.24 | 10 |
| Yield EPS, % | 17.91 | 3 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 47.29 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 47.62 $ | 0 $ | 0 $ | -0.693 % | 0 % | 0 % |
| Month | 30.17 $ | 47.29 $ | 47.29 $ | +56.75 % | 0 % | 0 % |
| Three month | 23.95 $ | 25.02 $ | 48.6 $ | +97.45 % | 0 % | 0 % |
| Half a year | 38.73 $ | 21.05 $ | 48.6 $ | +22.1 % | 0 % | 0 % |
| Year | 48.94 $ | 21.05 $ | 52.4 $ | -3.37 % | 0 % | 0 % |
| 3 years | 25.91 $ | 10.97 $ | 52.4 $ | +82.52 % | 0 % | 0 % |
| 5 years | 29.22 $ | 10.97 $ | 87.83 $ | +61.84 % | 0 % | 0 % |
| 10 years | 10.97 $ | 10.97 $ | 87.83 $ | +431.08 % | 0 % | 0 % |
| Year to date | 44.36 $ | 21.05 $ | 48.6 $ | +6.61 % | 0 % | 0 % |
Insider trading
| Insider | Transaction date | Date of disclosure | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
| BAKER BROS. ADVISORS LP Director |
30.06.2025 | 30.06.2025 | Purchase | 44 | 28 842 000 | 655500 | 0 | 1.28 | link |
| Chadwick Jeremy G Officer |
23.05.2025 | 23.05.2025 | Purchase | 30.17 | 77 688 | 2575 | 0 | 0.01 | link |
| JEFFREY ALBERS Director |
26.08.2024 | 26.08.2024 | Purchase | 47.78 | 238 900 | 5000 | 0 | 0.01 | link |
| Booth Bruce Director |
09.07.2024 | 09.07.2024 | Sale | 38.21 | 17 345 800 | 453960 | 0 | -0.88 | link |
| Chadwick Jeremy G Chief Operating Officer |
23.05.2024 | 23.05.2024 | Sale | 34.99 | 90 099 | 2575 | 0 | -0.01 | link |
| Booth Bruce Director |
15.03.2024 | 15.03.2024 | Sale | 40.46 | 2 903 570 | 71764 | 0 | -0.14 | link |
| Booth Bruce Director |
14.03.2024 | 15.03.2024 | Sale | 39.98 | 2 230 040 | 55779 | 0 | -0.11 | link |
| Booth Bruce Director |
13.03.2024 | 13.03.2024 | Sale | 42.23 | 5 880 740 | 139255 | 0 | -0.27 | link |
| Atlas Venture Fund X, L.P. 10% Owner |
13.03.2024 | 13.03.2024 | Sale | 42.23 | 1 020 490 | 24165 | 0 | -0.05 | link |
| Atlas Venture Fund X, L.P. 10% Owner |
13.03.2024 | 13.03.2024 | Sale | 42.23 | 4 860 250 | 115090 | 0 | -0.22 | link |
| Booth Bruce Director |
12.03.2024 | 13.03.2024 | Sale | 41.98 | 6 839 300 | 162918 | 0 | -0.32 | link |
| Booth Bruce Director |
11.03.2024 | 13.03.2024 | Sale | 42.85 | 2 193 230 | 51184 | 0 | -0.1 | link |
| Jacobs Bruce N. Chief Financial Officer |
04.03.2024 | 04.03.2024 | Sale | 41.86 | 164 677 | 3934 | 0 | -0.01 | link |
| Mainolfi Nello Chief Executive Officer |
08.12.2022 | 08.12.2022 | Purchase | 2.08 | 20 800 | 10000 | 0 | 0.02 | link |
| Atlas Venture Fund X, L.P. 10% Owner |
01.11.2022 | 01.11.2022 | Sale | 30.6 | 515 549 | 16848 | 0 | -0.03 | link |
| Atlas Venture Fund X, L.P. 10% Owner |
01.11.2022 | 01.11.2022 | Sale | 30.6 | 1 841 570 | 60182 | 0 | -0.12 | link |
| Booth Bruce Director |
01.11.2022 | 01.11.2022 | Sale | 30.6 | 2 357 120 | 77030 | 0 | -0.15 | link |
| Atlas Venture Fund X, L.P. 10% Owner |
31.10.2022 | 01.11.2022 | Sale | 30.23 | 797 558 | 26383 | 0 | -0.05 | link |
| Atlas Venture Fund X, L.P. 10% Owner |
31.10.2022 | 01.11.2022 | Sale | 30.23 | 2 848 840 | 94239 | 0 | -0.18 | link |
| Booth Bruce Director |
31.10.2022 | 01.11.2022 | Sale | 30.23 | 3 646 400 | 120622 | 0 | -0.23 | link |
| Atlas Venture Fund X, L.P. 10% Owner |
28.10.2022 | 01.11.2022 | Sale | 30 | 597 450 | 19915 | 0 | -0.04 | link |
| Atlas Venture Fund X, L.P. 10% Owner |
28.10.2022 | 01.11.2022 | Sale | 30 | 2 134 050 | 71135 | 0 | -0.14 | link |
| Booth Bruce Director |
28.10.2022 | 01.11.2022 | Sale | 30 | 2 731 500 | 91050 | 0 | -0.18 | link |
| Mainolfi Nello Chief Executive Officer |
17.10.2022 | 17.10.2022 | Purchase | 2.08 | 124 243 | 59732 | 0 | 0.12 | link |
| Jacobs Bruce N. Chief Financial Officer |
17.10.2022 | 17.10.2022 | Purchase | 2.08 | 20 800 | 10000 | 0 | 0.02 | link |
| BVF PARTNERS L P/IL Director |
27.05.2022 | 31.05.2022 | Purchase | 14.78 | 966 154 | 65369 | 0 | 0.13 | link |
| BVF PARTNERS L P/IL Director |
26.05.2022 | 31.05.2022 | Purchase | 14.21 | 3 183 850 | 224057 | 0 | 0.44 | link |
| BVF PARTNERS L P/IL Director |
06.05.2022 | 09.05.2022 | Purchase | 19.25 | 1 925 000 | 100000 | 0 | 0.19 | link |
| BVF PARTNERS L P/IL Director |
05.05.2022 | 09.05.2022 | Purchase | 19.6 | 2 940 000 | 150000 | 0 | 0.29 | link |
| BVF PARTNERS L P/IL Director |
31.01.2022 | 31.01.2022 | Purchase | 40.7 | 1 400 410 | 34408 | 0 | 0.08 | link |
Main owners
| Institutions | Volume | Share, % |
| Baker Brothers Advisors, LLC | 5 995 928 | 9.81 |
| Atlas Venture Life Science Advisors, LLC | 5 858 262 | 9.59 |
| Price (T.Rowe) Associates Inc | 5 335 712 | 8.73 |
| BVF Inc. | 5 161 801 | 8.45 |
| Wellington Management Group, LLP | 4 815 558 | 7.88 |
| Vanguard Group Inc | 3 997 564 | 6.54 |
| Avoro Capital Advisors LLC | 3 775 000 | 6.18 |
| Blackrock Inc. | 3 566 611 | 5.84 |
| Artal Group S.A. | 2 530 735 | 4.14 |
| State Street Corporation | 1 894 279 | 3.1 |
Contained in ETF
| ETF | Share, % | Profitability for 1 year, % | Commission, % |
| Future Tech ETF | 0.31198 | 479.5 | 0.35 |
| Principal Healthcare Innovators ETF | 0.31198 | -3.92 | 0.35 |
| iShares Morningstar Small-Cap Growth ETF | 0.09127 | 570.49 | 0.06 |
| iShares Morningstar Small-Cap ETF | 0.04667 | 301.34 | 0.25 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Dr. Nello Mainolfi M.D., Ph.D. | Co-Founder, President, CEO & Director | 975.2k | 1979 (46 years) |
| Mr. Bruce N. Jacobs CFA | Chief Financial Officer | 648.3k | |
| Dr. Jared A. Gollob M.D. | Chief Medical Officer | 637.81k | 1965 (60 years) |
| Ms. Ellen V. Chiniara Esq., J.D. | Chief Legal Officer & Corporate Secretary | N/A | 1959 (66 years) |
| Dr. Jeremy G. Chadwick Ph.D. | Chief Operating Officer | N/A | 1963 (62 years) |
| Ms. Karen Weisbach | Head of People & Culture | N/A | |
| Dr. Bruce L. Booth DPHIL, Ph.D. | Co-Founder & Independent Chairman | 79.19k | 1974 (51 year) |
| Dr. Juliet Williams B.A Ph.D. | Head of Research | N/A |
About company
Address: United States, Watertown, 200 Arsenal Yards Boulevard - Open in google maps, Open in yandex maps
Website: http://www.kymeratx.com
Website: http://www.kymeratx.com
